Company: AZN
Filing Date: 2025-05-02
Form Type: 6-K
Source: 0001654954-25-005021
Chunk: 4

Company: ASTRAZENECA PLC
Filing Date: 2025-05-02
Form: 6-K
Chunk 4
---
 Global Asthma Network. The Global Asthma Report 2022. [Online]. Available at: http://globalasthmareport.org/resources/Global_Asthma_Report_2022.pdf . [Last accessed: May 2025].

4. Davis J, et al . Burden of asthma among patients adherent to ICS/LABA: A real-world study. J Asthma . 2019 Mar;56(3):332-340.

5. Buhl R, et al . One-year follow up of asthmatic patients newly initiated on treatment with medium- or high-dose inhaled corticosteroid-long-acting b2-agonist in UK primary care settings. Respir Med . 2020 Feb: 162:105859.

6. U.S. Centers for Disease Control and Prevention (CDC). Most Recent National Asthma Data. [Online]. Available at: https://www.cdc.gov/asthma/most_recent_national_asthma_data.htm . [Last accessed: May 2025].

7. Fernandes AG, et al . Risk factors for death in patients with severe asthma. J Bras Pneumol . 2014; 40 (4): 364-372.

8. Clinicaltrials.gov. A 12-week Study to Assess the Efficacy and Safety of Budesonide and Formoterol Fumarate Metered Dose Inhaler Relative to Budesonide Metered Dose Inhaler in Participants with Inadequately Controlled Asthma (LITHOS) [Online]. Available at: https://clinicaltrials.gov/study/NCT05755906?limit=25&term=LITHOS&rank=1 . [Last Accessed: May 2025].

9. Clinicaltrials.gov. A 24-Week Efficacy and Safety Study to Assess Budesonide and Formoterol Fumarate Metered Dose Inhaler in Adult and Adolescent Participants with Inadequately Controlled Asthma (VATHOS) [Online]. Available at: https://clinicaltrials.gov/study/NCT05202262?limit=25&term=VATHOS&rank=1 . [Last Accessed: May 2025].

10. AstraZeneca Data on File. 2025. REF-270910.

#### Matthew Bowden

#### Company Secretary

#### AstraZeneca PLC
<div align='center'>SIGNATURES</div>

Pursuant to the requirements of the Securities Exchange